The annual awards show also saw Cytopoint by Zoetis awarded a “highly commended” status in the same category.
The category in question is sponsored by CM Research which, since 2014, has been asking vets to nominate products which they believe is the best new veterinary product of the year.
More than 400 nominations were received for the 2019 award.
VMA awards chairman Claire Edmunds said: “This year’s winners will still get their moment of glory on stage next March at the rescheduled event.
“We can also announce that the event is likely to include some additional categories to recognise campaigns and initiatives undertaken during the COVID-19 pandemic.”
Rebecca Bryant, marketing manager for pet health therapeutics at Elanco, said: “The UK team is proud to be part of the launch of this innovative, first-in-class product, which has already enriched the lives of thousands of pet owners and their dogs living with OA.”
Carlos Michelsen, managing director of CM Research, said: “Thanks to the continued success of Cytopoint, Zoetis achieved highly commended status.
“But it was Elanco that came in as award winners, with their novel veterinary pharmaceutical product Galliprant taking the crown. Congratulations to Elanco.”
CM Research is a specialist veterinary and pet market research agency that conducts research for veterinary pharmaceuticals across more than 20 countries.
It is also the owner of Vetspanel, the largest online community of veterinarians and veterinary nurses.